Therapeutic evaluation of intralesional 5% 5-fluorouracil in condyloma acuminata.
Condyloma acumianata is one of the most common virally transmitted diseases. Its prevalence has increased many fold throughout the world. Because all the currently available treatments yield low cure rates with side effects, the search for a new alternative continues. Topically, 5-fluorouracil (5-FU) has been in used for many years to treat various skin diseases. When applied topically in condyloma acuminata, 5-FU results in low cure rates with high recurrences. Therefore, intralesional 5% 5-FU is being evaluated to determine its therapeutic efficacy in condyloma acuminata.
Pall
Anuj
A
Department of Dermatology, Venereology and Leprosy, Government Medical College and Hospital, Punjab, India.
Mahajan
Bharat Bhushan
BB
Puri
Karanjit Pal Singh
KP
Gupta
Rajesh Rani
RR
D000293:Adolescent; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D003218:Condylomata Acuminata / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D005831:Genital Diseases, Female / Q000188:drug therapy / Q000473:pathology; D005832:Genital Diseases, Male / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil